Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.
CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.
The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.
CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.
The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.
CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.
Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.
CONMED Corporation (NYSE: CNMD) reported strong first quarter results for 2023, achieving sales of $295.5 million, a 21.9% increase year over year, with a 25.1% rise in constant currency. Domestic sales grew by 25.4%, while international sales rose 17.8% year over year. However, diluted net earnings per share (GAAP) fell to $0.06, an 87.2% decline compared to Q1 2022. Adjusted diluted net earnings per share decreased by 5.7% to $0.66. The company has raised its full-year revenue guidance to between $1.205 billion and $1.250 billion, up from a previous range of $1.170 billion to $1.220 billion. Additionally, adjusted diluted net earnings per share guidance was increased to a range of $3.30 to $3.50.
CONMED Corporation (NYSE: CNMD) will announce its Q1 2023 financial results on
CONMED Corporation (NYSE: CNMD) announced that its Annual Meeting of Stockholders will take place on May 24, 2023, at 1:30 p.m. ET at its headquarters in Largo, FL, and virtually. Shareholders of record by March 28, 2023 can vote. Further details will be in a definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2023, available on CONMED's website.
CONMED specializes in surgical devices for minimally invasive procedures across various medical fields. The company emphasizes its commitment to addressing risks and uncertainties, notably those arising from the ongoing COVID-19 pandemic.
CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair and CEO, along with Todd W. Garner, CFO, will participate in a virtual fireside chat at the KeyBanc Life Sciences and MedTech Investor Forum. This event is scheduled for 9:00 a.m. ET on March 22, 2023. A live audio webcast will be available on the Company’s website, with a replay following the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and gastroenterology. For more information, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED specializes in providing surgical devices and equipment for minimally invasive procedures in various medical specialties, including orthopedics and gastroenterology. Further details can be found on their official website.
CONMED reported Q4 2022 sales of $250.9 million, an 8.4% decline year-over-year, with domestic revenue down 3.9% and international revenue down 13.8%. Diluted net earnings per share (GAAP) rose 14.7% to $0.86, while adjusted earnings fell 60.7% to $0.42. For full-year 2022, sales grew 3.4% to $1,045.5 million. However, the company reported a diluted net loss per share of $2.68, contrasting with earnings of $1.94 in 2021. For 2023, CONMED forecasts revenue between $1.170 billion and $1.220 billion, with adjusted EPS expected at $3.20 to $3.45.
FAQ
What is the current stock price of CONMED Corporation (CNMD)?
What is the market cap of CONMED Corporation (CNMD)?
What does CONMED Corporation specialize in?
Where is CONMED Corporation headquartered?
How many employees does CONMED Corporation have?
What are the main product specialties of CONMED Corporation?
What are the primary reporting units of CONMED Corporation?
In which regions does CONMED Corporation generate most of its revenue?
What is the mission of CONMED Corporation?
How does CONMED Corporation ensure customer and patient satisfaction?
What recent achievements has CONMED Corporation made?
What is CONMED Corporation's approach to innovation?
